Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session - Head and neck cancer

5432 - Preliminary results from a phase 2 trial of tipifarnib in Squamous Cell Carcinomas (SCCs) with HRAS mutations.


22 Oct 2018


Proffered paper session - Head and neck cancer


Cytotoxic Therapy;  Translational Research

Tumour Site

Head and Neck Cancers


Alan Ho


Annals of Oncology (2018) 29 (suppl_8): viii372-viii399. 10.1093/annonc/mdy287


A.L. Ho1, N. Chau2, J. Bauman3, K. Bible4, A. Chintakuntlawar4, M.E. Cabanillas5, D.J. Wong6, I. Braña Garcia7, M.S. Brose8, V. Boni9, C. Even10, M. Razaq11, V. Mishra12, K. Bracken13, D. Wages13, C. Scholz13, A. Gualberto13

Author affiliations

  • 1 Medical Oncology, Memorial Sloan Kettering Cancer Center, 10065 - New York City/US
  • 2 Medical Oncology, Dana-Farber Cancer Institute, 02215 - Boston/US
  • 3 Hematology/oncology, Fox Chase Cancer Center, Philadelphia/US
  • 4 Medical Oncology, Mayo Clinic, 55905 - Rochester/US
  • 5 Department Of Endocrine Neoplasia And Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston/US
  • 6 Medicine, Hematology/oncology, UCLA - School of Medicine, 90095 - Los Angeles/US
  • 7 Medical Oncology, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 8 Medical Oncology, Abramson Cancer Center at the University of Pennsylvania School of Medicine, 19104 - Philadelphia/US
  • 9 Medical Oncology, START Madrid-CIOCC HM Hospital Sanchinarro, 28050 - Madrid/ES
  • 10 Department Of Head And Neck Surgical & Medical Oncology, Gustave Roussy Institute, 94800 - Villejuif/FR
  • 11 Medical Oncology, Stephenson Cancer Center, 73104 - Oklahoma City/US
  • 12 Diagnostics, Kura Oncology, 92121 - San Diego/US
  • 13 Development, Kura Oncology, 02142 - Cambridge/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5432


HRAS is a proto-oncogene overexpressed and mutated in head and neck squamous cell carcinomas (HNSCC), bladder, thyroid and salivary gland tumors, among others. Although discovered over 40 years ago, no therapies are yet approved targeting mutant HRAS. Tipifarnib is a potent and highly selective inhibitor of farnesyltransferase, a critical enzyme required for the proper function of HRAS. This Phase 2 study (NCT02383927) was conducted to test the hypothesis that inhibition of HRAS oncogenic activity could translate to objective responses in solid tumors.


The study was designed to enroll patients (pts) into 2 single-arm study cohorts: Cohort 1 (thyroid cancer) and Cohort 2 (other solid tumors), each one with a 2-stage design to determine overall response rate (ORR) as the primary objective. This design has 80% power to detect a difference between 10% and 30% ORR at one-sided significance level of 0.087. A study cohort was to be considered positive if at least 4 responses were observed (N = 36, 18 evaluable subjects/cohort). For enrollment, pts must have an HRAS mutation, locally advanced/unresectable and/or metastatic, and RECIST v1.1 measurable disease. Tipifarnib was dosed at 900 mg orally twice daily on days 1-7 and 15-21 of 28-day cycles.


As of May 1, 2018, 37 pts have been treated, including 11 pts with HRAS mutated HNSCC and 2 pts with HRAS mutated SCC. Tipifarnib was generally well tolerated, with fatigue, myelosuppression, nausea and vomiting constituting the most common adverse events (all grades). 7 HNSCC pts are currently evaluable for efficacy; 5 (71%) achieved a confirmed partial response with a median duration of response of 14.1 months (95% CI: 1.4-17.3 mo), exceeding the pre-specified null hypothesis. Importantly, no HRAS mutated HNSCC pt experienced an objective response on their last therapy prior to receiving tipifarnib (including platinum, immunotherapy and cetuximab +/- chemotherapy regimens).


Encouraging activity of tipifarnib was observed in pts with HRAS mutant HNSCCs. The study met its predefined success criteria and has been amended to continue enrolling HRAS mutant HNSCC pts, as well as pts with SCC, other than HNSCC, with HRAS mutations into a new Cohort 3.

Clinical trial identification


Legal entity responsible for the study

Kura Oncology.


Kura Oncology.

Editorial Acknowledgement

Not applicable


A.L. Ho, N. Chau, J. Bauman, K. Bible, A. Chintakuntlawar, M.E. Cabanillas, D.J. Wong, I. Braña Garcia, M.S. Brose, V. Boni, C. Even, M. Razaq: Clinical investigator for Study KO-TIP-001. V. Mishra, K. Bracken, C. Scholz: Stock ownership and employee: Kura Oncology. D. Wages: Consultant: Kura Oncology. A. Gualberto: Chief Medical Officer and stock ownership: Kura Oncology.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.